Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9. https://doi.org/10.1016/S0140-6736(02)08512-4.

Article  CAS  PubMed  Google Scholar 

Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76. https://doi.org/10.1056/NEJMoa050516.

Article  CAS  PubMed  Google Scholar 

Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104(3):760–7.

CAS  PubMed  Google Scholar 

Srinivasan A, Gilmore R, van Langenberg D, et al. Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn’s disease. Ther Adv Gastroenterol. 2022;15:17562848211070940. https://doi.org/10.1177/17562848211070940.

Article  CAS  Google Scholar 

Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;13(3):522–30.

Article  CAS  PubMed  Google Scholar 

Srinivasan A, Ding NS, Langenberg DV, et al. Therapeutic drug monitoring in inflammatory bowel disease: optimising therapeutic effectiveness of biologics. In: Ding NS, De Cruz P, editors., et al., Biomarkers in inflammatory bowel diseases. Springer: Berlin; 2019. p. 243–55.

Chapter  Google Scholar 

Katz L, Gisbert JP, Manoogian B, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn’s disease patients with loss of response. Inflamm Bowel Dis. 2012;18(11):2026–33. https://doi.org/10.1002/ibd.22902.

Article  PubMed  Google Scholar 

Magro F, Bastos R, Marques M, et al. Infliximab dose intensification by shortening infusion intervals. Inflamm Bowel Dis. 2008;14(3):432–4. https://doi.org/10.1002/ibd.20314.

Article  CAS  PubMed  Google Scholar 

Baert F, Glorieus E, Reenaers C, et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn’s patients. J Crohns Colitis. 2013;7(2):154–60. https://doi.org/10.1016/j.crohns.2012.03.018.

Article  PubMed  Google Scholar 

Kopylov U, Mantzaris GJ, Katsanos KH, et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab. Alimentery Pharmacol Ther. 2011;33(3):349–57. https://doi.org/10.1111/j.1365-2036.2010.04523.x.

Article  CAS  Google Scholar 

Srinivasan A, Vasudevan A, McFarlane A, et al. Anti-TNF re-induction is as effective, simpler, and cheaper compared with dose interval shortening for secondary loss of response in Crohn’s disease. J Crohns Colitis. 2018;12(3):280–8.

Article  PubMed  Google Scholar 

Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF-α therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;14(4):550.e2-557.e2.

Article  Google Scholar 

De Gregorio M, Lee T, Krishnaprasad K, et al. Higher anti-tumor necrosis factor-α levels correlate with improved radiologic outcomes in Crohn’s perianal fistulas. Clin Gastroenterol Hepatol. 2022;20(6):1306–14.

Article  PubMed  Google Scholar 

Bossuyt P, Dreesen E, Rimola J, et al. Infliximab exposure associates with radiologic evidence of healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2021;19(5):947–54.

Article  CAS  PubMed  Google Scholar 

Papamichael K, Rakowsky S, Rivera C, et al. Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic, and histologic remission in Crohn’s disease. Inflamm Bowel Dis. 2018;24(10):2266–71.

Article  PubMed  PubMed Central  Google Scholar 

Papamichael K, Rakowsky S, Rivera C, et al. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis. Aliment Pharmacol Ther. 2018;47(4):478–84.

Article  CAS  PubMed  Google Scholar 

Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–83.

Article  CAS  PubMed  Google Scholar 

Yarur A, Kanagala V, Stein D, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017;45(7):933–40.

Article  CAS  PubMed  Google Scholar 

Desai DC, Dherai AJ, Strik A, et al. Personalized dosing of infliximab in patients with inflammatory bowel disease using a Bayesian approach: a next step in therapeutic drug monitoring. J Clin Pharmacol. 2023;63(4):480–9.

Article  CAS  PubMed  Google Scholar 

Xu Z, Mould D, Hu C, et al. Population pharmacokinetic analysis of infliximab in pediatrics using integrated data from six clinical trials. Clin Pharmacol Drug Dev. 2012;1(203)

Strik AS, Löwenberg M, Mould DR, et al. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. Scand J Gastroenterol. 2021;56(2):145–54.

Article  CAS  PubMed  Google Scholar 

Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108(1):40.

Article  CAS  PubMed  Google Scholar 

Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–8.

Article  CAS  PubMed  Google Scholar 

Srinivasan AR. Treat to target in Crohn’s disease: a practical guide for clinicians. World J Gastroenterol. 2024;30(1):50–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn’s disease. J Crohns Colitis. 2013;7(9):736–43.

Article  PubMed  Google Scholar 

Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341–53.

Article  PubMed  Google Scholar 

Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147(6):1296–307.

Article  CAS  PubMed  Google Scholar 

Gibson DJ, Ward MG, Rentsch C, et al. determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020;51(6):612–28.

Article  PubMed  Google Scholar 

Srinivasan A, De Cruz P, Sam M, et al. Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses. J Gastroenterol Hepatol. 2023;38(5):724–32.

Article  CAS  PubMed  Google Scholar 

Post TM, Freijer JI, Ploeger BA, et al. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. 2008;35:185–202.

Article  PubMed  PubMed Central  Google Scholar 

Srinivasan A, De Cruz P, Van Langenberg DR. Anti-TNF-associated immunogenicity: use a retroactive drug but a proactive approach. Gut. 2021;70(4):812–3.

Article  PubMed  Google Scholar 

Magro F, Fernandes S, Patita M, et al. The influence of subclinical active inflammation on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients. J Crohn’s Colitis. 2024. https://doi.org/10.1093/ecco-jcc/jjae014. (Epub 19 Jan 2024).

Article